Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$2.02 USD
-0.03 (-1.46%)
Updated May 30, 2024 04:00 PM ET
After-Market: $2.02 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Cyclacel Pharmaceuticals, Inc. [CYCC]
Reports for Purchase
Showing records 21 - 40 ( 75 total )
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q22: 3 Clinical Trials Enrolling, Initial Data Soon, Cash Through 1H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Fadra Publication Shows MCL1 Suppression & Synergy with Venetoclax in CLL
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Oral Fadraciclib & CYC140 Trials Progressing, Funded Thru Mid-2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Outlines 2022 Catalysts, Updates Clinical Programs, Vastly Undervalued
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: Oral Fadraciclib Trials Progressing Swiftly, Funded to Early 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Clinical Pipeline Progressing As Expected, Funded Into Early 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Solid Tumor Clinical Pipeline Expanding, Well-Funded Into Early 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Annual ROTH Conference: Cancer Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q20: Convenient Oral Formulations Should Be the Path Forward, Well-Funded
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J